DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

Completed

Conditions: Baseline Epidemiologic Assessment

Interventions: Drug: MorphaBond ER
Drug: Comparator Drug

First Posted Date: 2019-07-25

Last Posted Date: 2021-03-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 17566

Registration Number: NCT04033094

Locations: 🇺🇸
Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Phase 1

Completed

Conditions: Mineralocorticoid Receptor Antagonist
Hypertension

Interventions: Drug: CS-3150
Drug: Moxifloxacin
Drug: Placebo matching moxifloxacin tablet
Drug: Placebo matching CS-3150

First Posted Date: 2019-07-15

Last Posted Date: 2019-07-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 55

Registration Number: NCT04019652

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2

Completed

Conditions: Adenocarcinoma Gastric Stage IV With Metastases
Adenocarcinoma - GEJ

Interventions: Drug: Trastuzumab deruxtecan

First Posted Date: 2019-07-10

Last Posted Date: 2024-04-09

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 79

Registration Number: NCT04014075

Locations: 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
USC Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸
UCLA Health, Santa Monica, California, United States

and more 33 locations

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A - 400 mg Fasting
Drug: Treatment B - 400 mg Fed
Drug: Treatment C - 200 mg Fed

First Posted Date: 2019-04-03

Last Posted Date: 2020-05-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT03901313

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Quizartinib
Drug: Fludarabine
Drug: Cytarabine
Drug: Intrathecal (IT) triple chemotherapy prophylaxis
Drug: Etoposide

First Posted Date: 2019-01-04

Last Posted Date: 2024-11-07

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 65

Registration Number: NCT03793478

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 25 locations

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Conditions: Acute Myeloid Leukemia With Gene Mutations

First Posted Date: 2018-11-20

Last Posted Date: 2020-04-15

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT03746912

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan (DS-8201a)
Drug: Capecitabine
Drug: Eribulin
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2018-11-07

Last Posted Date: 2024-04-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 557

Registration Number: NCT03734029

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Jilin Cancer Hospital, Chang chun, Jilin, China

and more 205 locations

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

Phase 1

Completed

Conditions: Drug Pharmacokinetics in Healthy Volunteers

Interventions: Drug: DS-8500a
Drug: Rosuvastatin

First Posted Date: 2018-10-09

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT03699774

Locations: 🇺🇸
Worldwide Clinical Trials (WCT) Early Phase Services, San Antonio, Texas, United States

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Early Phase 1

Completed

Conditions: Food Effects on Pharmacokinetics

Interventions: Drug: Milademetan Treatment A
Drug: Milademetan Treatment B
Drug: Milademetan Treatment C

First Posted Date: 2018-08-27

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 18

Registration Number: NCT03647202

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Early Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Milademetan
Drug: Posaconazole
Drug: Itraconazole

First Posted Date: 2018-08-03

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 36

Registration Number: NCT03614455

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy